Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Claudio, Dazzi"'
Autor:
Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, Giovanna Esposito, Claudio Dazzi, Luigi Cavanna, Marco Angelo Burgio, Francesco Rosetti, Simona Rizzato, Floriana Morgillo, Saverio Cinieri, Antonello Veccia, Maximilan Papi, Giuseppe Tonini, Vittorio Gebbia, Serena Ricciardi, Daniele Pozzessere, Alessandra Ferro, Claudia Proto, Raffaele Costanzo, Manolo D’Arcangelo, Manuela Proietto, Piera Gargiulo, Raimondo Di Liello, Laura Arenare, Filippo De Marinis, Lucio Crinò, Fortunato Ciardiello, Nicola Normanno, Ciro Gallo, Francesco Perrone, Cesare Gridelli, Alessandro Morabito
Publikováno v:
Journal of Thoracic Oncology. 17:1086-1097
Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were available in non-Asian patients. BEVERLY is an Italian, multicenter, randomize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c041711688f84a28d633db8a0f052417
https://doi.org/10.1016/j.jtho.2022.05.008
https://doi.org/10.1016/j.jtho.2022.05.008
Autor:
Paola Ulivi, Dino Amadori, Lucio Crinò, Vienna Ludovini, Daniele Calistri, Chiara Bennati, Rita Chiari, Alessandro Gamboni, Marita Mariotti, Nicoletta De Luigi, Claudia Casanova, Laura Capelli, Maximilian Papi, Claudio Dazzi, Elisa Chiadini, Angelo Delmonte, Elisabetta Petracci, Matteo Canale
Supplementary legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a1776a59a757395036284beb73f44e6
https://doi.org/10.1158/1078-0432.22465229
https://doi.org/10.1158/1078-0432.22465229
Autor:
Federico Cappuzzo, Lucio Crinò, Gabriella Fontanini, Agnese Proietti, Rossella Bruno, Greta Alì, Emilio Bria, Claudio Verusio, Francesca Mazzoni, Gabriele Minuti, Enrica Capelletto, Francesco Grossi, Fausto Barbieri, Domenico Galetta, Cesare Gridelli, Alessandro Morabito, Gloria Borra, Filippo de Marinis, Diego Luigi Cortinovis, Diana Giannarelli, Laura Bonanno, Angelo Delmonte, Antonio Chella, Claudio Dazzi, Federica D'Incà, Marcello Tiseo, Rita Chiari, Lorenza Landi
Purpose:MET-deregulated NSCLC represents an urgent clinical need because of unfavorable prognosis and lack of specific therapies. Although recent studies have suggested a potential role for crizotinib in patients harboring MET amplification or exon 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be6d6151db514789b70a16810282ae9a
https://doi.org/10.1158/1078-0432.c.6527793
https://doi.org/10.1158/1078-0432.c.6527793
Autor:
Paola Ulivi, Dino Amadori, Lucio Crinò, Vienna Ludovini, Daniele Calistri, Chiara Bennati, Rita Chiari, Alessandro Gamboni, Marita Mariotti, Nicoletta De Luigi, Claudia Casanova, Laura Capelli, Maximilian Papi, Claudio Dazzi, Elisa Chiadini, Angelo Delmonte, Elisabetta Petracci, Matteo Canale
Purpose: To analyze the impact of TP53 mutations on response to first-line tyrosine kinase inhibitors (TKI) in patients with EGFR-mutated non–small cell lung cancer (NSCLC).Experimental Design: 136 EGFR-mutated NSCLC patients receiving first-line T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23d47bb549e33379e5931ad94663ae8
https://doi.org/10.1158/1078-0432.c.6525968
https://doi.org/10.1158/1078-0432.c.6525968
Autor:
Paola Ulivi, Dino Amadori, Lucio Crinò, Vienna Ludovini, Daniele Calistri, Chiara Bennati, Rita Chiari, Alessandro Gamboni, Marita Mariotti, Nicoletta De Luigi, Claudia Casanova, Laura Capelli, Maximilian Papi, Claudio Dazzi, Elisa Chiadini, Angelo Delmonte, Elisabetta Petracci, Matteo Canale
Relation of TP53 mutations and clinical characteristics of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::039484f724f298b67c10c5e59cad9947
https://doi.org/10.1158/1078-0432.22465238
https://doi.org/10.1158/1078-0432.22465238
Autor:
Paola Ulivi, Dino Amadori, Lucio Crinò, Vienna Ludovini, Daniele Calistri, Chiara Bennati, Rita Chiari, Alessandro Gamboni, Marita Mariotti, Nicoletta De Luigi, Claudia Casanova, Laura Capelli, Maximilian Papi, Claudio Dazzi, Elisa Chiadini, Angelo Delmonte, Elisabetta Petracci, Matteo Canale
Distribution of disruptive and non-disruptive mutations in the different types of TP53 mutations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11e44015238e6e527258bbb5c74f3225
https://doi.org/10.1158/1078-0432.22465241.v1
https://doi.org/10.1158/1078-0432.22465241.v1
Autor:
Paola Ulivi, Dino Amadori, Lucio Crinò, Vienna Ludovini, Daniele Calistri, Chiara Bennati, Rita Chiari, Alessandro Gamboni, Marita Mariotti, Nicoletta De Luigi, Claudia Casanova, Laura Capelli, Maximilian Papi, Claudio Dazzi, Elisa Chiadini, Angelo Delmonte, Elisabetta Petracci, Matteo Canale
Association between TP53 and EGFR mutations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::327c5e4f2f415859ce8e3780347f776c
https://doi.org/10.1158/1078-0432.22465235
https://doi.org/10.1158/1078-0432.22465235
Autor:
Paola Ulivi, Dino Amadori, Lucio Crinò, Vienna Ludovini, Daniele Calistri, Chiara Bennati, Rita Chiari, Alessandro Gamboni, Marita Mariotti, Nicoletta De Luigi, Claudia Casanova, Laura Capelli, Maximilian Papi, Claudio Dazzi, Elisa Chiadini, Angelo Delmonte, Elisabetta Petracci, Matteo Canale
ORR and DCR observed in EGFR exon 19 deleted patients in relation to TP53 mutations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28f63894fe73e9a03752c8c467533ec0
https://doi.org/10.1158/1078-0432.22465232
https://doi.org/10.1158/1078-0432.22465232
Autor:
Paola Ulivi, Dino Amadori, Lucio Crinò, Vienna Ludovini, Daniele Calistri, Chiara Bennati, Rita Chiari, Alessandro Gamboni, Marita Mariotti, Nicoletta De Luigi, Claudia Casanova, Laura Capelli, Maximilian Papi, Claudio Dazzi, Elisa Chiadini, Angelo Delmonte, Elisabetta Petracci, Matteo Canale
Supplementary Figure 1. a) PFS and b) OS of TP53 exon 8 mutated patients, other TP53 non-disruptive mutated patients and TP53 wt/disruptive mutated patients in the overall case series. c) PFS and d) OS of TP53 exon 8 mutated patients, other TP53 non-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1056cf9950064e2534730323974a99f8
https://doi.org/10.1158/1078-0432.22465244.v1
https://doi.org/10.1158/1078-0432.22465244.v1
Autor:
Federico Cappuzzo, Lucio Crinò, Gabriella Fontanini, Agnese Proietti, Rossella Bruno, Greta Alì, Emilio Bria, Claudio Verusio, Francesca Mazzoni, Gabriele Minuti, Enrica Capelletto, Francesco Grossi, Fausto Barbieri, Domenico Galetta, Cesare Gridelli, Alessandro Morabito, Gloria Borra, Filippo de Marinis, Diego Luigi Cortinovis, Diana Giannarelli, Laura Bonanno, Angelo Delmonte, Antonio Chella, Claudio Dazzi, Federica D'Incà, Marcello Tiseo, Rita Chiari, Lorenza Landi
Supplementary information of the manuscript Table S1. Outcome to prior therapy in cohort A and cohort B Table S2. Response according to molecular profile in Cohort A Table S3. Response according to molecular profile in Cohort B Tables S4. Efficacy ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d94b2341e1366fae212685122fed65d
https://doi.org/10.1158/1078-0432.22471143
https://doi.org/10.1158/1078-0432.22471143